Gavish − Galilee Bioapplications Ltd. was established in 2000, and holds sole rights to the technology and to the intellectual properties of Migal − Galilee Technology Center. Its objectives are to identify technologies which have significant commercial potential, to protect Migal's intellectual assets, to establish subsidiary companies, to form strategic partnerships and to grant concessions for industrial development.
Gavish has a number of subsidiaries dealing with development of medications, cosmetic products, genetic medicine, agricultural development and diagnostics.
Gavish cooperates with other research institutes, hospitals and the leading industrial companies in Israel and abroad.
Stockholders in Gavish are:
- F.I.B.I. Investment House Ltd.
- Mivtach Shamir Technologies
- Neopharm Ltd.
- Migal- Galilee Technology Center